Cytosorbents Corp
CTSO
88 hedge funds and large institutions have $58.8M invested in Cytosorbents Corp in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 17 closing their positions.
2,267% more call options, than puts
Call options by funds: $71K | Put options by funds: $3K
0.55% more ownership
Funds ownership: 40.91% → 41.46% (+0.55%)
3% less funds holding
Funds holding: 91 → 88 (-3)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
21% less capital invested
Capital invested by funds: $74.6M → $58.8M (-$15.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Avenir Corporation
Alexandria,
Virginia
|
+$1.39M |
| 2 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
+$650K |
| 3 |
Goldman Sachs
New York
|
+$604K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$425K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.61M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$716K |
| 3 |
Walleye Capital
New York
|
-$392K |
| 4 |
Walleye Trading
New York
|
-$201K |
| 5 |
JP Morgan Chase
New York
|
-$189K |
CTSO Hedge Fund Activity: Q1 2022 in Review
88 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cytosorbents Corp (CTSO) for Q1 2022, worth a combined $58.8M — down 21% from $74.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTSO and 15 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 24 added.
The largest buyer was Avenir Corporation, adding an estimated $1.39M. The largest seller was Redmile Group, cutting an estimated $1.61M.
- 88 institutional investors held Cytosorbents Corp (CTSO) as of Q1 2022, down from 91 in Q4 2021.
- Funds reported $58.8M of Cytosorbents Corp stock for Q1 2022, down 21% quarter-over-quarter.
- 15 funds opened new Cytosorbents Corp positions in Q1 2022 and 17 closed out, a net change of -2 holders.
- The largest Cytosorbents Corp buyer in Q1 2022 was Avenir Corporation, an estimated $1.39M added.
- The largest Cytosorbents Corp seller in Q1 2022 was Redmile Group, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2022.